Account
Sign In
Home
Daily Diary
Asset Class
Fixed Income
Currencies
US Equity
Specialty
Global Equity & Income
Commodities
Sectors
Healthcare
Financial Services
Basic Materials
Consumer Cyclicals
Telecom Services
Energy
Transportation
Consumer Staples
Industrials
Utilities
Technology
Real Estate
Latest
Columnist Conversation
Video
Street Notes
Authors
Bruce Kamich
Jim Cramer
Jim "Rev Shark" DePorre
Brian Sozzi
Helene Meisler
Jonathan Heller
Roger Arnold
- See All -
Options
RMPIA
Switch Product
Action Alerts PLUS
Daily Swing Trade Archive
Income Seeker
Quant Ratings
Retirement
Stocks Under $10
TheStreet
Top Stocks
Trifecta Stocks
Information Provided By:
Visit TheFly.com
TheFly.com Free Trial
Fly News Breaks for December 1, 2015
AZN
Get Breaking Institutional Stock News For
Free
with a 14 day trial
AstraZeneca upgraded to Overweight from Underweight at Morgan Stanley
Dec 1, 2015 | 11:38 EDT
News For AZN From the Last 2 Days
AZN
Get Breaking Institutional Stock News For
Free
with a 14 day trial
AstraZeneca backs FY24 core EPS view up low double-digit to low teens percentage
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
AZN
Get Breaking Institutional Stock News For
Free
with a 14 day trial
AstraZeneca reports Q1 core EPS $2.06, consensus $1.22
Apr 25, 2024 | 05:49 EDT